Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Christoph Rosak,1 Gabriele Mertes21Specialist for Internal Medicine, Endocrinology and Diabetes, Sachsenhausen Hospital, Frankfurt/Main, Germany; 2Retired, Mülheim, GermanyAbstract: The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperg...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f256b809ffb548318d75dd940d72f69e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Christoph Rosak,1 Gabriele Mertes21Specialist for Internal Medicine, Endocrinology and Diabetes, Sachsenhausen Hospital, Frankfurt/Main, Germany; 2Retired, Mülheim, GermanyAbstract: The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state.Keywords: acarbose, prediabetes, type 2 diabetes, patient considerations, side effects |
|---|